Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis-Reference-Cited by-同舟云学术

Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

Published:2021-03 Issue:4 Volume:10 Page:325-335
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Aguilar-Serra Javier¹,Gimeno-Ballester Vicente²,Pastor-Clerigues Alfonso¹³,Milara Javier¹³⁴⁵,Marti-Bonmati Ezequiel¹³,Trigo-Vicente Cristina⁶⁷,Cortijo Julio¹³⁵

Affiliation:

1. Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain

2. Department of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain

3. Department of Pharmacy, University General Hospital Consortium, Valencia, Spain

4. Department of Pharmacology, Research Foundation of General Hospital of Valencia, Valencia, Spain

5. CIBER (ES), Respiratory Research, Health Institute Carlos III, Valencia, Spain

6. Department of Pharmacy, C.R.P. Nuestra Señora del Pilar, Zaragoza, Spain

7. Department of Pharmacology, Universidad San Jorge, Zaragoza, Spain

Abstract

Aim: To assess the cost–effectiveness of first-line treatment with dacomitinib compared with gefitinib in patients newly diagnosed with advanced NSCLC EGFR-positive in the context of Spain. Materials & methods: A partitioned survival model was developed including costs, utilities and disutilities to estimate quality-adjusted life-year (QALY) and incremental cost–effectiveness ratio when treating with dacomitinib versus gefitinib. Results: Dacomitinib presented higher QALYs (0.51) compared with gefitinib (0.45). Dacomitinib costs were €33,061 in comparison with €26,692 for gefitinib arm. An incremental cost–effectiveness ratio of €111,048 was obtained for dacomitinib. Conclusion: Dacomitinib was more effective in terms of QALYs gained than gefitinib. However, to obtain a cost–effectiveness alternative, a discount greater than 25% in dacomitinib acquisition cost is required.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0233

Reference40 articles.

1. Cancer statistics, 2019

2. New molecularly targeted therapies for lung cancer

3. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

4. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

5. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open‐label, single‐dose, crossover trial;Clinical and Translational Science;2023-10-19

3. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC);Expert Opinion on Pharmacotherapy;2022-07-04

4. Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2021-10-11